Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS), McKesson (MCK) and Enhabit, Inc (EHAB)
Aclaris Therapeutics: Hold Rating Amid Mixed Trial Outcomes and Strategic Uncertainties
Stifel Maintains Aclaris Therapeutics(ACRS.US) With Hold Rating, Raises Target Price to $3
Stifel Nicolaus Sticks to Its Hold Rating for Aclaris Therapeutics (ACRS)
Aclaris Therapeutics | 10-Q: Q3 2024 Earnings Report